On the other hand, when anti–TGF-β was administered with the chemotherapy combination CDDP-Eri plus anti–PD-L1, it significantly delayed tumor growth and significantly improved animal survival (Figure 5A and Supplemental Figure 5, D and E), particularly in comparison with the chemotherapy combination alone or the chemotherapy plus anti–PD-L1 combination. Here, TGFB1 is linked to neoplasm.